annb0t
Top 20
MELBOURNE, Australia and INDIANAPOLIS, Jan. 13, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today provides an update on its commercial and operational performance for the quarter ended 31 December 2024 (Q4 2024).(PRNewsfoto/Telix Pharmaceuticals Limited)
Sustained revenue growth
Q4 2024 unaudited revenue of approximately US$142 million (AU$218 million)[1], represents an increase of 46% over the prior year corresponding quarter (Q4 2023: US$...
>>> Read more: Telix Exceeds FY24 Guidance with US$142M Q4 Revenue
Sustained revenue growth
Q4 2024 unaudited revenue of approximately US$142 million (AU$218 million)[1], represents an increase of 46% over the prior year corresponding quarter (Q4 2023: US$...
>>> Read more: Telix Exceeds FY24 Guidance with US$142M Q4 Revenue
